Novo Nordisk launches a next generation of FlexPen®

Novo NordiskNovo Nordisk announced the launch of a next generation of FlexPen® at the European Association for the Study of Diabetes (EASD) Annual Meeting. The new insulin injection device builds upon the high standards set by the current version of FlexPen®, with new features providing improved safety, convenience and ease of use for people with diabetes. FlexPen® is already the most widely used prefilled insulin device in the world(1), benefiting millions of people with diabetes worldwide.

The next generation of FlexPen® requires 30% less force when injecting, resulting in a significantly lower injection force compared with SoloSTAR® (2,3,4). Like the current version of FlexPen®, the next generation of FlexPen® provides superior dose accuracy in comparison to SoloSTAR® (2,5,6). In addition, the new device provides a range of new design features aimed at improving safety and simplicity for people with diabetes.

Among the new design features are coloured cartridges, labels and packaging designed to aid insulin type identification for patients. For ease of handling everyday insulin injections, the next generation of FlexPen® has an innovative simple twist mechanism to attach and detach the needle. This makes the device the first pen to be designed for use with a new generation of needles, which have a patented state-of-the-art attachment interface.

"This next generation of FlexPen® is very welcome because it makes the injection process more comfortable for patients," said Professor Andreas Pfützner, Institute for Clinical Research and Development, Mainz, Germany. "It introduces key features that will go a long way towards improving their compliance with prescribed treatment."

The next generation of FlexPen® has been tested among patients to assess if the new features translated into actual patient preference. In total, 95% of patients who tried the next generation of FlexPen® said they would prefer to use it, over the current version of FlexPen®. Eighty-nine percent found it more convenient to use, 98% said it took less effort to inject and 83% felt it was safer to operate than the current version of FlexPen®.(7)

The next generation of FlexPen® is available globally from late 2008.

About the next generation of FlexPen®
FlexPen® is the world’s most widely used prefilled insulin pen, trusted daily by millions of people with diabetes(1,8). The next generation of FlexPen® represents the latest advance in prefilled insulin pens from Novo Nordisk, designed to be simple and convenient to use, and helping to reduce the burden of living with diabetes.

The next generation of FlexPen® is a result of more than 25 years of research and development of insulin delivery systems undertaken since Novo Nordisk invented the insulin pen. Compared to other insulin delivery devices that have to be manually loaded with insulin cartridges, prefilled pens are ready to use, eliminating the step of loading insulin into the delivery device. The next generation of FlexPen® features a single-step dose-setting mechanism, portability and a discreet ‘non-medical’ appearance.

With the next generation of FlexPen® it is not possible to set a dose larger than that remaining in the pen. It permits dose corrections without loss of insulin, and provides doses in one-unit increments up to 60 units per injection (each pen contains 300 units in total). The dose scale of the next generation of FlexPen® automatically returns to zero after injection to allow visual confirmation of dose delivery.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit www.novonordisk.com.

References
1) Estimated number of patients using FlexPen®, based on worldwide sales in number of packs sold, IMS worldwide data Q2'08 and Daily Defined Dosage (DDD) for insulin as issued by WHO.
2) Pfützner A et al. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin 2008; 24(9): 2545-2549.
3) Rissler J et al. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin. Pharmacother 2008; 9(13): 2217-2222.
4) SoloSTAR®, a prefilled injection device, is a registered trademark of Sanofi-Aventis.
5) Asakura T et al. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin 2008; 24(5): 1429–1434.
6) Hänel H et al. Differences in the Dose Accuracy of Insulin Pens. J Diabetes Sci Technol 2008; 2(3): 478–481.
7) Sommavilla B et al. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother 2008; 9(13): 2223–2232.
8) Reimer T et al. Instruction time, Intuitiveness and Patient Acceptance of a Prefilled and a Reusable Insulin Delivery Device - The NovoMix® 30 FlexPen® and the HumaPen® Luxura™. ADA Abstract Book 2007; 56(Suppl 1): A2101-PO.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...